A risk evaluation and mitigation strategy for extended-release and long-acting (ER/LA) opioid analgesics was approved by the Food and Drug Administration in 2012. The authors' objective was to assess frequency of opioid tolerance and urine drug testing for individuals initiating ER/LA opioid analgesics.